免疫检查点抑制剂诱导的1型糖尿病:从其分子机制到临床实践
Yun Kyung Cho1,2, Chang Hee Jung1,2
1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Diabetes & metabolism journal
|July 24, 2023
概括
免疫检查点抑制剂 (ICI) 可以导致1型糖尿病 (T1DM),这是一个罕见但严重的副作用. 早期检测和胰岛素治疗对于管理这种ICI诱导的T1DM至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 抗CTLA-4和抗PD-1等免疫检查点抑制剂 (ICI) 越来越多地用于癌症治疗.
- 免疫相关不良事件 (irAEs) 是已知的ICI并发症.
- 由ICI诱导的1型糖尿病 (ICI-T1DM) 是一种新兴的irAE.
研究的目的:
- 审查ICI-T1DM的特征和病原性.
- 要突出ICI-T1DM的临床表现和潜在机制.
- 强调意识,早期检测和ICI-T1DM管理的重要性.
主要方法:
- 对ICI-T1DM报告病例的文献综述.
- 临床特征,表现和病变发生的分析.
- 与经典的1型糖尿病相比.
主要成果:
- ICI-T1DM与抗PD-1,抗PDL1或抗CTLA-4疗法一起发生,单独或组合.
- 超过一半的病例存在糖尿病酸性酸性.
- 主要机制涉及T细胞刺激,原因是胰腺小岛的PD-1/PD-L1通路中断.
结论:
- ICI-T1DM是一种罕见的,可能危及生命的紧急情况,需要医疗意识.
- 早期发现和查是必不可少的.
- 胰岛素注射仍然是唯一的治疗方法;进一步的研究可能会揭示预防策略.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Pathophysiology of Diabetes
1.0K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.0K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Diabetes: Symptoms, Diagnosis, and Complications
599
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
599
Dipeptidyl Peptidase 4 Inhibitors
213
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
213


